Clinical Trial Detail

NCT ID NCT02639182
Title A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Agensys, Inc.
Indications

renal cell carcinoma

Therapies

AGS16F

Axitinib

Age Groups: adult senior

No variant requirements are available.